<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255333</url>
  </required_header>
  <id_info>
    <org_study_id>INNO-105-901</org_study_id>
    <nct_id>NCT00255333</nct_id>
  </id_info>
  <brief_title>INNO-105 in Patients With Solid Tumors</brief_title>
  <official_title>A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Weekly Intravenous INNO-105 in Adult Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovive Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovive Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The safety, tolerability and pharmacokinetics of INNO-105, an investigational anticancer
      drug, are being studied in patients with solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Development of this compound was discontinued.
  </why_stopped>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INNO-105</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have a histologically or cytologically confirmed diagnosis of a solid malignancy
             (patients may have either measurable or nonmeasurable disease).

          2. Be ≥18 years old.

          3. Not eligible for effective therapy likely to provide clinical benefit.

          4. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2.

          5. Acceptable pretreatment clinical laboratory results.

          6. Life expectancy of greater than 12 weeks.

        Exclusion Criteria:

          1. Have received previous treatment with INNO-105.

          2. Have an active, uncontrolled systemic infection considered opportunistic, life
             threatening, or clinically significant at the time of treatment.

          3. Are pregnant or lactating.

          4. Have a psychiatric disorder(s) that would interfere with consent, study participation,
             or follow-up.

          5. Have received any chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major
             surgery, or irradiation, whether conventional or investigational, within 2 weeks of
             treatment in this study.

          6. Have not recovered from acute toxicity of all previous therapy prior to enrollment.

          7. Have symptomatic or untreated central nervous system (CNS) metastases.

          8. Have a susceptibility to hypotension, bradycardia, and/or hypopnea, such as patients
             with known coronary heart disease, arrhythmias, cerebral vascular disease, and chronic
             obstructive airways disease (CO2-retaining).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Casey Cunningham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mary Crowley Medical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Sausville, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Greenebaum Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2005</study_first_submitted>
  <study_first_submitted_qc>November 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2005</study_first_posted>
  <last_update_submitted>May 11, 2007</last_update_submitted>
  <last_update_submitted_qc>May 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2007</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

